A unique commercially viable recombinant manufacturing platform for human fibrinogen (rhFib) & thrombin (rhThrbroad
RECOFIB · Horizon Europe grant · 2022-04-01–2023-12-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-ACCELERATOROPEN-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2021-ACCELERATOROPEN-01. CORDIS record →
Objective
We have developed the RECOFIB platform, a market first recombinant production platform for human fibrinogen (rhFib) & thrombin (rhThr). Using Chinese Hamster Ovary Cells (CHO) expression technology & patented upstream purification processes, we are the first producer of fully intact & functional recombinant fibrinogen and active thrombin at commercially acceptable cost ending reliance on blood plasma. Our RECOFIB platform can produce individual fibrinogen variants whose specific functional properties can now be fully harnessed-a breakthrough discovery. From these individual variants, we can develop customized products for [1] bioactive topical hemostats to stop excessive bleeding during surgery; [2] medical implant coating reducing antibiotic resistance of MRSA bacterial biofilms and [3] supply of rhFib variants & rhThr as OEM products. Additional benefits of our rhFib variants compared to plasma fibrinogen include more stability, 10100X higher purity, and improved safety profile.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| FIBRIANT BV | NL | coordinator | €2,500,000 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.